Menu

Blog

Sep 18, 2021

Excision’s CRISPR gene editing therapy for HIV is heading into human testing after FDA clearance

Posted by in categories: bioengineering, biotech/medical

A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing.

Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical trials after the FDA cleared an investigational new drug application, according to the company’s press release.

EBT-101 is under development as a potential virus-clearing treatment for patients with HIV—or, put in the company’s words, “a potential functional cure for chronic HIV.”

Leave a reply